BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 10429625)

  • 1. Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
    Fernberg JO; Wiklund T; Monge O; Hall KS; Saeter G; Alvegård TA; Strander H
    Acta Orthop Scand Suppl; 1999 Jun; 285():62-8. PubMed ID: 10429625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
    Fernberg JO; Hall KS
    Acta Orthop Scand Suppl; 2004 Apr; 75(311):77-86. PubMed ID: 15188669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
    Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
    Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current trials and new aspects in soft tissue sarcoma of adults.
    Issels RD; Schlemmer M
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant chemotherapy and postoperative radiotherapy in high-risk soft tissue sarcoma patients defined by biological risk factors-A Scandinavian Sarcoma Group study (SSG XX).
    Sundby Hall K; Bruland ØS; Bjerkehagen B; Zaikova O; Engellau J; Hagberg O; Hansson L; Hagberg H; Ahlström M; Knobel H; Papworth K; Zemmler M; Goplen D; Bauer HCF; Eriksson M
    Eur J Cancer; 2018 Aug; 99():78-85. PubMed ID: 29929092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
    Tanaka K; Mizusawa J; Naka N; Kawai A; Katagiri H; Hiruma T; Matsumoto Y; Tsuchiya H; Nakayama R; Hatano H; Emori M; Watanuki M; Yoshida Y; Okamoto T; Abe S; Asanuma K; Yokoyama R; Hiraga H; Yonemoto T; Morii T; Ae K; Nagano A; Yoshikawa H; Fukuda H; Ozaki T; Iwamoto Y
    BMC Cancer; 2019 Sep; 19(1):890. PubMed ID: 31492159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: study protocol of the target selection phase III CHIC-STS trial.
    Filleron T; Le Guellec S; Chevreau C; Cabarrou B; Lesluyes T; Lodin S; Massoubre A; Mounier M; Poublanc M; Chibon F; Valentin T
    BMC Cancer; 2020 Jul; 20(1):716. PubMed ID: 32736540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
    Davis EJ; Chugh R; Zhao L; Lucas DR; Biermann JS; Zalupski MM; Feng M; Wong SL; Jacobson J; Zyczynski L; Reinke D; Metko G; Baker LH; Schuetze SM
    Eur J Cancer; 2015 Sep; 51(13):1794-802. PubMed ID: 26066736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma.
    Worden FP; Taylor JM; Biermann JS; Sondak VK; Leu KM; Chugh R; McGinn CJ; Zalupski MM; Baker LH
    J Clin Oncol; 2005 Jan; 23(1):105-12. PubMed ID: 15625365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group.
    Alvegård TA; Sigurdsson H; Mouridsen H; Solheim O; Unsgaard B; Ringborg U; Dahl O; Nordentoft AM; Blomqvist C; Rydholm A
    J Clin Oncol; 1989 Oct; 7(10):1504-13. PubMed ID: 2674336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy for soft tissue sarcoma--current concepts and review].
    Umeda T; Ishii T; Hatakeyama K; Wakita H
    Gan To Kagaku Ryoho; 1993 Oct; 20(13):1937-44. PubMed ID: 8215466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating soft tissue sarcomas with adjuvant chemotherapy.
    Patrikidou A; Domont J; Cioffi A; Le Cesne A
    Curr Treat Options Oncol; 2011 Mar; 12(1):21-31. PubMed ID: 21384115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
    Judson I; Verweij J; Gelderblom H; Hartmann JT; Schöffski P; Blay JY; Kerst JM; Sufliarsky J; Whelan J; Hohenberger P; Krarup-Hansen A; Alcindor T; Marreaud S; Litière S; Hermans C; Fisher C; Hogendoorn PC; dei Tos AP; van der Graaf WT;
    Lancet Oncol; 2014 Apr; 15(4):415-23. PubMed ID: 24618336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
    Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
    Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Responses of 109 adult soft tissue sarcoma patients to chemotherapy].
    Qiu MZ; Xu F; Wang SS; Luo HY; Wang F; Li FH; Sun XF; Xu GC; Lin TY; Huang HQ; Jiang WQ; Guan ZZ; Xu RH
    Ai Zheng; 2007 Dec; 26(12):1344-9. PubMed ID: 18076798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma: a conventional and network Meta-analysis.
    Hua Q; Xu G; Zhao L; Zhang T
    J Chemother; 2021 Sep; 33(5):319-327. PubMed ID: 33501892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
    Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
    Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VIP (etoposide, ifosfamide, and cisplatin) in patients with previously treated soft tissue sarcoma.
    Moon JY; Baek SW; Ryu H; Choi YS; Song IC; Yun HJ; Jo DY; Kim S; Lee HJ
    Medicine (Baltimore); 2017 Jan; 96(4):e5942. PubMed ID: 28121937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of soft tissue sarcoma in childhood and adolescence. A report of the German Cooperative Soft Tissue Sarcoma Study.
    Koscielniak E; Jürgens H; Winkler K; Bürger D; Herbst M; Keim M; Bernhard G; Treuner J
    Cancer; 1992 Nov; 70(10):2557-67. PubMed ID: 1482503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.